Isabelle Ray-Coquard
Overview
Explore the profile of Isabelle Ray-Coquard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
472
Citations
14225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferraioli D, Fuso L, Chiado F, Russo C, Rossi L, Borella F, et al.
Eur J Surg Oncol
. 2025 Mar;
51(7):109749.
PMID: 40086217
Introduction: In advanced epithelial ovarian cancer (AEOC), debulking surgery with posterior pelvic exenteration (PPE) is performed in 35-70 % of the patients to achieve no macroscopic residual disease. This study...
2.
Zucchi D, Marinello D, Tani C, Fulvio G, Aguilera S, Benachi A, et al.
Orphanet J Rare Dis
. 2025 Mar;
20(1):112.
PMID: 40065363
Background: Rare and complex diseases can have a significant impact on family life, and managing the reproductive aspects of patients of childbearing age with rare diseases is often difficult and...
3.
Ferraioli D, Borella F, Meurer M, Lebreton C, Penel N, Bertucci F, et al.
Int J Gynecol Cancer
. 2025 Mar;
:101692.
PMID: 40044476
Objectives: Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of ovarian tumors, and they typically have a poor prognosis. The available data on the management of these tumors...
4.
Ray-Coquard I, Ledermann J, DeFazio A, Okamoto A, Gershenson D
Int J Gynecol Cancer
. 2025 Mar;
35(3):101669.
PMID: 40022843
More than half of all gynecological cancers are classified as rare (annual incidence <6 per 100,000), and present significant challenges in diagnosis, management, and research. Rare cancers collectively comprise more...
5.
Bigenwald Dr C, Roos-Weil D, Pages A, Helias-Rodzewicz Z, Copie-Bergman C, Nashvi M, et al.
Blood Adv
. 2025 Feb;
PMID: 40009752
Malignant histiocytoses (MH) are rare and poorly understood cancers, with no established therapeutic guidelines. We conducted a national retrospective study of MH diagnosed in France between 2000 and 2023. All...
6.
Le Saux O, McNeish I, DIncalci M, Narducci F, Ray-Coquard I
Int J Gynecol Cancer
. 2025 Feb;
35(3):101667.
PMID: 39987717
High-grade serous carcinoma is the most lethal gynecological malignancy. Although serous tubal intra-epithelial carcinoma is increasingly recognized as a precursor to high-grade serous carcinoma, its optimal management remains controversial. This...
7.
Gershenson D, Ledermann J, Ray-Coquard I
Int J Gynecol Cancer
. 2025 Feb;
35(3):101677.
PMID: 39983367
No abstract available.
8.
Barbier de Reulle C, Rebotier M, Chopin N, Rossi L, Treilleux I, Meeus P, et al.
Eur J Obstet Gynecol Reprod Biol
. 2025 Jan;
307:13-20.
PMID: 39879740
Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among...
9.
Rosso R, Turinetto M, Borella F, Chopin N, Meeus P, Laine A, et al.
Oncologist
. 2025 Jan;
30(1).
PMID: 39846983
Ovarian clear cell carcinoma (OCCC) accounts for ~10% of all epithelial ovarian cancers and is considered a different entity from the more common high-grade serous ovarian carcinoma (HGSC), with distinct...
10.
Bogani G, Moore K, Ray-Coquard I, Lorusso D, Matulonis U, Ledermann J, et al.
Gynecol Oncol
. 2025 Jan;
193:30-40.
PMID: 39764856
Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need...